ArticleAmerican journal of translational research2019
Intra-articular injection of etoricoxib-loaded PLGA-PEG-PLGA triblock copolymeric nanoparticles attenuates osteoarthritis progression.
Article in American journal of translational research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Drug Delivery Systems for the Treatment of Knee Osteoarthritis: A Systematic Review of In Vivo Studies.International journal of molecular sciences · 2021Pooled it
- Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review.International journal of molecular sciences · 2020Pooled it
- Panaxatriol exerts anti-senescence effects and alleviates osteoarthritis and cartilage repair fibrosis by targeting UFL1.Journal of advanced research · 2025Article
- Nanomaterial-Based Drug Delivery Systems Targeting Functional Cells for Osteoarthritis Treatment: Mechanisms, Challenges and Future Prospects.International journal of nanomedicine · 2025Review
- Research progress on biodegradable polymer-based drug delivery systems for the treatment of knee osteoarthritis.Frontiers in bioengineering and biotechnology · 2025Review
- Therapeutic Controlled Release Strategies for Human Osteoarthritis.Advanced healthcare materials · 2025Review
- Development and Applications of PLGA Hydrogels for Sustained Delivery of Therapeutic Agents.Gels (Basel, Switzerland) · 2024Review
- Nanomaterial-assisted theranosis of bone diseases.Bioactive materials · 2023Review
- Polymeric Nanoparticles for Drug Delivery in Osteoarthritis.Pharmaceutics · 2022Review
- Microcarriers in application for cartilage tissue engineering: Recent progress and challenges.Bioactive materials · 2022Review
- Nanomedicine and regenerative medicine approaches in osteoarthritis therapy.Aging clinical and experimental research · 2022Review
- T2 mapping for knee cartilage degeneration in young patients with mild symptoms.BMC medical imaging · 2022Article
- Investigating a Curcumin-Loaded PLGA-PEG-PLGA Thermo-Sensitive Hydrogel for the Prevention of Alzheimer's Disease.Antioxidants (Basel, Switzerland) · 2022Article
- Article
- Targeted treatment for osteoarthritis: drugs and delivery system.Drug delivery · 2021Review
- Small extracellular vesicles in combination with sleep-related circRNA3503: A targeted therapeutic agent with injectable thermosensitive hydrogel to prevent osteoarthritis.Bioactive materials · 2021Article
- Osteoarthritis In Vitro Models: Applications and Implications in Development of Intra-Articular Drug Delivery Systems.Pharmaceutics · 2021Review
- Current Nanoparticle-Based Technologies for Osteoarthritis Therapy.Nanomaterials (Basel, Switzerland) · 2020Review
- Biomedical nanomaterials for immunological applications: ongoing research and clinical trials.Nanoscale advances · 2020Review
- Therapeutic Manipulation of Macrophages Using Nanotechnological Approaches for the Treatment of Osteoarthritis.Nanomaterials (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The current pharmacological therapies for osteoarthritis (OA) are mainly focused on symptomatic relief of pain and inflammation through the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Etoricoxib is a cyclooxygenase-2 (COX-2) selective NSAID with a higher cyclooxygenase-1 (COX-1) to COX-2 selectivity ratio than the other COX-2 selective NSAIDs and a lower risk of gastrointestinal toxicity compared to traditional NSAIDs. In this study, we first evaluated the anti-inflammatory and chondro-protective effects of etoricoxib on interlecukin-1β-stimulated human osteoarthritic chondrocytes. We found that etoricoxib not only inhibited the expression of inflammation mediators COX-2, prostaglandin E
Indexed as
Identifiers
31814887PMC6895527W2998522918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.